Gujarat Fluorochemicals Limited

Gujarat Fluorochemicals is India's largest and most vertically integrated fluoropolymer producer and is among the leading global PTFE manufacturers. Its PTFE capacity of about 21,000 tonnes per annum is estimated at 8–9% of world capacity (Nuvama via Business Standard, Sep 2025). Integration runs from fluorspar mining in Morocco, through hydrofluoric acid, chloromethanes and refrigerant gases, to PTFE, PVDF, FEP, PFA, FKM and other high-performance polymers. This backbone of more than 30 years of fluorine chemistry now supports three growth vectors. The first is specialty fluoropolymers for semiconductors, EV/BESS, hydrogen and solar. The second is HFC refrigerants (R32 from March 2026, with R134a planned) under India's Kigali entitlements. The third is battery materials through majority-owned GFCL EV Products, which offers LiPF6 salt, electrolytes, LFP cathode active material, PVDF binders and, prospectively, natural-graphite anode material from an integrated complex at Jolva, Gujarat. The core chemicals franchise funds a planned ~INR 6,000 cr battery build-out through FY2028, so near-term returns are diluted while option value is created.

What the company does. GFL manufactures and sells fluorine-based and chlorine-based chemicals and polymers from three Gujarat manufacturing sites: Ranjitnagar, Dahej and Jolva. It supplies domestic and export customers, with a stated sales emphasis on Europe and the USA. Its May 2026 investor presentation describes four business verticals:

1. Fluoropolymers: PTFE (granular, fine powder, dispersion), micropowders, PFA, PVDF, FEP, FKM fluoroelastomers and PPA processing aids. This is the largest vertical, at about 58% of revenue in FY2025 (ICICI Direct Q1 FY26 note).

2. Fluorochemicals: refrigerants (R22, R32, R125, R410A blends, with R134a planned) plus HF-based, TFE-based and KF-based fluorospecialty intermediates for agrochemicals and pharmaceuticals.

3. Bulk chemicals: caustic soda, chloroform, methylene dichloride (MDC) and carbon tetrachloride (CTC). Most of this output is captive feedstock for R22 and the fluoropolymer chain; the surplus is sold.

4. Battery materials (GFCL EV Products Ltd, majority-owned): LiPF6 salt, formulated electrolytes, high-performance additives, LFP cathode active material (CAM), PVDF/PTFE cathode binders, and a natural graphite anode active material (NG-AAM) facility under construction.

Company's own characterization. The company describes itself as a leading Indian chemicals company supplying fluoropolymers and fluorochemicals to the global market. It calls itself the largest PTFE and fluoropolymer manufacturer in India, developing grades for "new-age" applications such as EVs, BESS and green hydrogen (investor presentation, 26 May 2026; paraphrased). It cites three core competencies: integrated plant operations, a proven 30-year legacy in fluorine chemistry, and industry leadership in fluoropolymers.

Independent characterization. GFL is best understood as a vertically integrated fluorine-value-chain processor transitioning toward advanced materials. Its economic engine has three parts:

• Low-cost captive inputs: fluorspar, HF, chloromethanes and R22 as the TFE monomer precursor.

• Conversion into PTFE and higher-value polymer grades, where customer qualification cycles create switching costs.

• Optionality in regulated refrigerant gases, where Montreal/Kigali Protocol quotas cap supply and support pricing.

The battery business reuses the same chemistry (HF and PF5 for LiPF6, VDF for PVDF binders). It is still pre-scale: FY2026 segment revenue was INR 33 cr against an EBITDA loss of INR 80 cr.

Revenue model.

Value-chain position. GFL sits mid-to-upstream. Most rivals buy HF or fluorspar; GFL is backward-integrated into fluorspar (Moroccan mine via GFL GM Fluorspar SA) and HF. It sells semi-finished polymers (resins, powders, dispersions) to processors and compounders, who make finished components such as seals, tubing, cable insulation, membranes and coatings. In battery materials it sells to electrolyte formulators and cell manufacturers.

Customer types and end-markets.

Stated strategic themes (paraphrased from FY2026 presentations and calls)

1. Leadership in fluoropolymers, moving up the value chain. Grow higher-performance grades (PFA, FKM, PVDF, FEP) for semiconductors, EV/BESS, clean energy, AI data centres and advanced automotive. Management guided ~25% FP growth for FY2026, later tempered by tariffs, and 17–20% FP growth for FY2027 (Aug 2026 call).

2. Maximize refrigerant entitlements under Kigali. Optimize HFC production and add capacity: R32 started Mar 2026, its expansion is due Q2 FY27 with full utilization in CY2027, and R134a is due within FY2027. The aim is to lock in baseline quotas before the HFC freeze.

3. Build a global, ex-China battery-materials champion. GFCL EV aims to be a leading supplier of battery materials, covering about 70% of LFP cell cost once anode is added. It plans ~INR 6,000 cr of capex by FY2028 (INR 2,300 cr in FY2027), targeting 2x asset turnover and 25%+ EBITDA margin at maturity, with full potential in FY2029.

4. Semiconductor and advanced materials. A new subsidiary (Jun 2026) and part of the INR 850 cr FY2027 chemicals capex target high-purity electronic specialty chemicals.

5. Trade defence and market access. GFL actively uses Indian trade-remedy law: PTFE anti-dumping on China and Russia, and anti-circumvention against Korea.

6. Capital efficiency. Working-capital reduction (192 to 149 days) and ROCE expansion are now explicit KPIs in presentations.

7. Corporate simplification. The ILFL amalgamation under the composite scheme.

Fluoropolymers (Chemicals segment)

The company sells under the GFL corporate brand; grade-level trade names such as "INOFLON" have been used historically but are n.v. for the current catalogue.

Battery materials (EV Products segment, GFCL EV Products Ltd)

The company states that its portfolio will address about 70% of LFP cell cost once anode is added. It also claims to be the only global company offering electrolyte salts, formulated electrolytes, CAM, AAM and binders under one roof (company claim, May 2026; not independently verified). Pricing models are not disclosed.

Sources: S&P Global Market Intelligence standardized statements (StockAnalysis), reconciled to company-reported revenue from operations. FY2026 PAT, EPS and dividend are from the audited results of 26 May 2026. EBITDA is computed here as PBT + finance cost + D&A, which is close to company-reported EBITDA but may differ slightly. FY2021 consolidated revenue from operations was ~INR 2,650 cr (sum of reported quarters); other FY2021 metrics are excluded because they could not be reconciled.

Income statement (INR crore unless stated)

Notes:

• FY2022–FY2024 PBT is derived from S&P line items (operating income + other income + FX gains − interest).

• FY2025 PBT (713) and FY2026 PBT (807) are as reported. FY2026 PBT is after an exceptional labour-code charge (~INR 15 cr post-tax at chemical-segment level per presentation; INR 3 cr post-tax consolidated in Q4).

• FY2022–FY2024 EPS is computed on 10.985 cr shares. FY2025 and FY2026 EPS are as reported.

• Dividends are on a cash-paid basis from the cash-flow statement. The FY2026 final dividend declared was INR 3 per share (ex-date 17 Sep 2026).

Margins (%)

Revenue CAGR: FY2022–FY2026 is 6.0% (4-year). Including FY2021 (INR ~2,650 cr), the FY2021–FY2026 5-year CAGR is ~13.5%.

Commentary: P&L. The five years form a full commodity-specialty cycle:

FY2022–FY2023 (up-cycle): Pandemic-era restocking, tight Chinese supply and strong refrigerant pricing lifted revenue 44% in FY2023 to a peak of INR 5,685 cr. EBITDA margins peaked at 37.5%, and the gross margin of nearly 54% shows pricing power.

FY2024 (inflection down): Global fluoropolymer destocking and Chinese oversupply cut revenue by a quarter. The EBITDA margin fell to 23%, while D&A and interest kept rising as capex continued counter-cyclically, so PAT fell 67%.

FY2025–FY2026 (slow recovery): Fluoropolymer volumes and new-grade mix recovered, but refrigerant headwinds (R22 quota cuts, US tariffs on R125) and the EV start-up losses (FY2026 EV EBITDA −INR 80 cr) capped growth. Gross margin recovered to 51%, a sign that chemicals pricing has normalized, but operating leverage was absorbed by higher depreciation (INR 367 cr vs INR 205 cr in FY2022) and pre-revenue EV overheads.

Run-rate inflection: Q1 FY2027 (revenue INR 1,588 cr, EBITDA INR 428 cr at 27%, PAT INR 219 cr) annualizes to roughly INR 6,350 cr revenue and INR 1,700 cr EBITDA. This suggests FY2027 could be the first year since FY2023 with meaningful earnings growth, if R32 and anti-dumping benefits persist.

Quarterly detail (consolidated, INR crore)

Notes:

• Q3 FY26 EBITDA is derived from a reported 24.2% margin.

• Q3 FY26 PAT is reported variously at INR 102–115 cr across sources, and INR 103 cr is used. This discrepancy is flagged.

• Q1 FY26 PAT is shown as INR 182 cr (adjusted) in the Q1 FY27 presentation versus INR 184 cr as reported.

• Q3 FY26 EPS is derived.

Balance sheet (INR crore, 31 March)

Notes:

• FY2025 equity includes ~INR 741 cr of additional paid-in capital, consistent with GFCL EV's external equity raise.

• FY2026 BVPS uses attributable equity of INR 7,866 cr. Some vendors show INR 696.7 using a 112.9 m share count, which is disputed.

• Goodwill is nil; the line is intangibles only.

Cash flow (INR crore)

Commentary: balance sheet and cash flow. GFL has funded a large, multi-year capex programme (~INR 4,330 cr cumulative capex over FY2022–FY2026) almost entirely from internal accruals. It also raised minority equity at the GFCL EV level (~INR 1,000 cr from Indian investors by FY2025; ~INR 430 cr from IFC and ~INR 1,200 cr from Middle Eastern sovereign funds in FY2026; ~INR 3,730 cr raised or tied up in total). Net debt has stayed in a tight INR 1,350–1,900 cr band.

Free cash flow has been negative for three years. Working capital is the structural weakness. Inventory doubled from INR 947 cr to INR 1,933 cr between FY2022 and FY2026, and the company's own working-capital metric reached 192 days at March 2026 before falling to 149 days in Q1 FY2027. The FY2026 rise in OCF to INR 961 cr (+76%) reflects a much smaller working-capital drag, which is an early positive inflection. CRISIL treats debt of group company Inox Wind and its subsidiary, where guaranteed by GFL, as adjusted debt (rationales 2024–2025). This off-balance-sheet contingent exposure is a governance and credit monitorable.

Ratios

Notes:

• FY2022 ROE and ROA use ending balances because the FY2021 balance sheet was not reconciled.

• ROIC assumes a 25% tax rate on EBIT ex-other income (30% for FY2026).

• The cash conversion cycle is DSO + DIO − DPO, computed from S&P data with DIO and DPO on cost of materials. It is not comparable with the company's "working capital days" metric (192 days at Mar-2026; 149 days at Jun-2026).

• The company reports adjusted FY2026 ROCE of 14.05% and ROE of 12.17%, excluding capital employed in capacity expansions of the last two years and CWIP including EV. Q1 FY2027 was 16.63% ROCE and 15.18% ROE on that basis (company, Aug 2026).

Commentary: returns. Reported returns on capital have been stuck in single digits since FY2024 because the denominator includes ~INR 1,500 cr+ of CWIP and pre-revenue EV assets. The company's adjusted metrics strip these out, which is fair as a measure of the mature business. On a fully loaded basis, however, investors are earning ~6% ROIC on an EV of over INR 52,000 cr. Hence the valuation relies on execution of the EV and specialty pipeline. CRISIL's sensitivity threshold for the AA+ rating is net debt/EBITDA sustained below 1.6x over the medium term (Mar 2026 rationale); at ~1.3x reported, headroom is adequate but not large given INR 3,150 cr of FY2027 capex.

Management guidance (Aug 2026)

• Fluoropolymer revenue growth of 17–20% in FY2027, supported by volumes, price increases, the anti-dumping duty and semiconductor-grade mix.

• R32 expansion commissioned in Q2 FY27, with full utilization in CY2027. R134a commissioned within FY2027.

• Battery materials revenue reaching three digits per quarter (INR 100 cr+) by Q4 FY27, with major expansion from FY2028. LFP final qualification by Q3 FY27; PVDF binders commercial in H1 FY27.

• FY2027 capex of INR 3,150 cr, with cumulative EV capex of ~INR 6,000 cr by FY2028 targeting 2x asset turnover and 25%+ EBITDA margin (full potential in FY2029).

• Continued working-capital reduction from the 149-day level.

Consensus expectations

Consensus implies ~28% revenue CAGR and ~29% EPS CAGR over three years (S&P). Applied to the FY2026 base, this suggests FY2029 revenue of roughly INR 10,500 cr and EPS of roughly INR 110. This is an illustrative computation from consensus growth rates, not company guidance.

Bull case

1. Chemicals earnings inflection is already visible. Q1 FY27 chemicals EBITDA rose 29% YoY to INR 458 cr at a 29% margin. Fluorochemicals revenue grew 52% on R32, and working capital fell by 43 days. If sustained, chemicals EBITDA could exceed INR 1,800 cr in FY2027 against INR 1,371 cr in FY2026.

2. Structural policy tailwinds compound. The PTFE anti-dumping duty addresses imports that made up ~60% of FY2025 Indian PTFE imports at sub-domestic prices. US tariffs have fallen from 50% to 18%, and supplier exits (3M) create share opportunities in Western markets.

3. Battery option is now funded and de-risked by third parties. IFC and Middle Eastern sovereign investors have committed ~USD 130 m and Indian investors ~INR 1,000 cr. LiPF6 is approved by major electrolyte makers, and Phase I capacity is contracted with anchor clients. Hitting the 25% margin and 2x asset-turnover targets on INR 6,000 cr of capex would imply ~INR 3,000 cr of EV EBITDA at maturity, more than double today's group EBITDA.

Bear case

1. Valuation already discounts success. At ~83x trailing and ~47x forward earnings and ~40x EV/EBITDA, the stock trades near consensus targets (~2% upside). Fully loaded ROIC is ~6%, so any slip in battery qualification or R32 pricing risks de-rating.

2. Battery economics are unproven against Chinese incumbents. EV losses widened to −INR 57 cr PAT in Q4 FY26. LFP commercialization has already moved to H2 FY27. LiPF6 and LFP are historically boom-bust, China-priced commodities, and asset-turnover and margin targets may prove optimistic.

3. Cash generation remains weak and policy-dependent. FCF has been negative for three straight years, and FY2027 capex of INR 3,150 cr exceeds likely OCF. Earnings depend on time-bound trade remedies, quota regimes and PFAS regulatory outcomes outside management's control. Group guarantees add contingent risk.

Analyst verdict

Gujarat Fluorochemicals is a high-quality, vertically integrated fluorine franchise in the middle of an expensive transformation. The mature chemicals business is regaining momentum after the FY2024 down-cycle. Q1 FY2027 delivered record revenue of INR 1,588 cr and a 29% chemicals EBITDA margin, helped by three overlapping supports: Indian anti-dumping protection on PTFE, newly commissioned R32 capacity under Kigali quotas, and easing US tariffs. This core is fundamentally sound, carries a AA+ credit rating and is being run more tightly on working capital.

The investment debate centres on GFCL EV. Management is committing roughly INR 6,000 cr to build an integrated ex-China battery-materials platform. External validation from IFC, Middle Eastern sovereign capital and qualification by major electrolyte makers is genuine. So far, however, the segment has generated INR 33 cr of revenue against INR 80 cr of EBITDA losses, and its timelines have already slipped once. Until LFP CAM and binders convert qualification into volume, group returns on capital will stay in single digits, and free cash flow will stay negative through at least FY2027.

At ~83x trailing earnings and ~40x EV/EBITDA, the market is pricing a large share of the bull case: chemicals EBITDA compounding plus a successful battery ramp by FY2028–FY2029. The consensus target sits only ~2% above the current price, which leaves limited margin of safety. We therefore view the stock as a fairly valued, execution-dependent compounder. Fundamental momentum is positive, but the risk/reward is balanced at current levels.

Investors should anchor on three tests over the next 12 months:

1. Chemicals EBITDA sustaining at least INR 450 cr per quarter.

2. Battery revenue reaching three digits per quarter by Q4 FY2027 with narrowing losses.

3. Working capital and leverage staying inside the CRISIL envelope.

Meeting all three would justify the premium and support an upgrade. Missing the battery milestones, or a reversal in trade protection or refrigerant pricing, would expose meaningful downside given the elevated multiple.

Figures marked n.v. could not be verified in the sources reviewed. Derived figures are labelled as such. Where sources conflicted (Q3 FY26 PAT, FY2026 share count, FY2026 segment revenue), both values and the discrepancy are noted. This document is not investment advice.

--